EGFR and lung adenocarcinoma: Among these patients, only 18.6% of all noted recurrences occurred in the locoregional site, which was significantly lower than those of EGFR wild-type counterparts (36.7%).10 Besides, recent reports revealed even better disease control with the administration of adjuvant tyrosine kinase inhibitor (TKI) compared with adjuvant chemotherapy.11-12 Based on the evidence, we made a hypothesis that PORT might not be beneficial in most patients with EGFR-mutant stage III-pN2 lung adenocarcinoma, except for those with extra risk factors for LRR.